

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Remdesivir for outpatients, duration of protection by COVID-19 vaccines, relative infectiousness of breakthrough infections and reinfections

Peer reviewed journals featured:

- Randomised controlled trials of:
 - Remdesivir to prevent severe COVID-19 in outpatients [here](#) and editorial [here](#)
 - Heterologous AD5-nCOV plus CoronaVac vs homologous CoronaVac vaccination [here](#)
- A clinical trial of homologous and heterologous COVID-19 booster vaccinations [here](#)
- A scoping review of randomised trials on non-pharmaceutical interventions for COVID-19 [here](#)
- Observational studies on:
 - Duration of protection against mild and severe disease by COVID-19 vaccines [here](#)
 - Infectiousness of vaccine breakthroughs, reinfections, and primary infections [here](#)
 - Mask-wearing in public places and risk compensation behaviour [here](#)
 - Infection dynamics of COVID-19 virus under lockdown and reopening [here](#)
 - Extended interval Comirnaty (Pfizer) vaccination and peak antibody generation [here](#)
 - The impact of SARS-CoV-2 prevention measures in Austrian schools [here](#)
 - Child masking and COVID-19–related closures in US childcare programs [here](#)
 - Clinical outcomes of patients with COVID-19–associated acute respiratory distress syndrome who underwent lung transplant [here](#)
- An editorial on menstruation and COVID-19 vaccination [here](#)
- Commentary on:
 - Severe COVID-19 in pregnancy and vaccination status [here](#)
 - Universal COVID-19 vaccines [here](#)
 - Anti-idiotypic antibodies in SARS-CoV-2 infection and vaccination [here](#)

Letters and correspondence discussed:

- Omicron variant neutralisation after Spikevax (Moderna) booster vaccination [here](#)
- Myocarditis after Comirnaty (Pfizer) vaccination in Israeli adolescents [here](#)
- Lung transplantation for COVID-19–related respiratory failure in the US [here](#)
- Waning Spikevax (Moderna) vaccine effectiveness against SARS-CoV-2 infection in Qatar [here](#)
- Effects of a prolonged booster interval on neutralisation of Omicron variant [here](#)
- Efficacy of antibodies and antiviral drugs against Omicron variant [here](#)
- Nursing home staff vaccination and COVID-19 outcomes in the US [here](#)

Guidance and reports

- The Cochrane Library published a systematic review on interleukin-1 blocking agents for treating COVID-19 [here](#)
- The Therapeutic Goods Administration (TGA) issued provisional approval for Comirnaty (Pfizer) as a booster in 16-17 year olds [here](#)

News and blogs

- Lower vaccination rates and higher death rates among minority ethnic groups in Britain [here](#)
- A NEJM audio interview on addressing the Omicron variant [here](#)
- A patient perspective on recovery from post-acute COVID-19 syndrome [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).